Physician profile
Brooke Moore
NPI 1205833704
$1,086.87
in general payments reported to CMS, 2019-2025
15 companies · $153 in 2025
The $153 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23.74 · 2021: $361 · 2022: $313 · 2023: $148 · 2024: $87.47 · 2025: $153.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $375 · Education: $13.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $374.96 |
| Education | $13.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $250.48 | 2021-2023 | Veltassa, Korsuva |
| Bayer Healthcare Pharmaceuticals INC. | $174.88 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $99.31 | 2021-2022 | |
| Daiichi Sankyo INC. | $98.81 | 2023-2024 | Injectafer |
| Aurinia Pharma U.S., INC. | $68.31 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $66.07 | 2021-2023 | Jynarque |
| Takeda Pharmaceuticals U.S.A., INC. | $59.42 | 2021-2024 | Gattex |
| Astellas Pharma US INC | $52.62 | 2025 | Veozah |
| Glaxosmithkline, LLC. | $50.04 | 2021 | |
| Calliditas Therapeutics US INC. | $40.18 | 2023-2025 | Tarpeyo |
| Fresenius USA Marketing, INC. | $36.39 | 2021-2022 | |
| Horizon Therapeutics Plc | $29.19 | 2022 | |
| Mallinckrodt Enterprises LLC | $23.74 | 2019 | |
| Puma Biotechnology, INC. | $19.44 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.99 | 2025 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brooke Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.